CoChat

Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies

Open access
Mitchell, S., Roso, S., Samuel, M., Pladevall-Vila, M. · 2016 · BMC Cardiovascular Disorders

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The aim of this study was to examine recommended target levels of low-density lipoprotein cholesterol (LDL-C) for hyperlipidaemia patients at high risk (i.e., with two or more risk factors or coronary heart disease or its risk equivalents) for cardiovascular disease (CVD); to determine LDL-C targets recommended by guidelines, and to examine the proportions of patients who do not achieve targeted LDL-C levels in real-world studies. METHODS: Electronic databases were searched: Medline, Medline In-Process, Embase, BIOSIS, and the Cochrane Library (1 January 2005 to 31 December 2013). Guideline searches were limited to publications in the last 5 years. There were no geographical or language restrictions. RESULTS: Seventeen guidelines and 42 observational studies that reported on high-risk hyperlipidaemia patients were identified. The National Cholesterol Education Program-Adult Treatment Panel III's LDL-C target levels were the most common guidelines used for patients with very high hyperlipidaemia. However, between 68 and 96 % of patients in the studies did not achieve an LDL-C goal <70 mg/dL, except in one study conducted in China (16.9 %). In high-risk patients, 61.8 to 93.8 % did not achieve a target of <100 mg/dL. Regarding common comorbidities, patients with concomitant CVD or diabetes were least likely to reach their target LDL-C goals. CONCLUSION: In patients with high risk for CVD, the majority of patients do not attain recommended LDL-C goals, highlighting worldwide suboptimal hyperlipidaemia management and missed opportunities for reduction of the patients CVD risk. Lipid-modifying management strategies need to be intensified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12872-016-0241-3

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow Chart for Study Inclusion and Exclusion. PRISMA preferred reporting items for systematic reviews and meta-analyses, RCT randomised, controlled trial
Fig. 1 Flow Chart for Study Inclusion and Exclusion. PRISMA preferred reporting items for systematic reviews and meta-analyses, RCT randomised, controlled trialCC BY · PubMed Central
Fig. 2 Patients (Very High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, <70 mg/dL (1.81 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, US United States. Notes: Treated and untreated patients. The N represents patients at high risk, a subset of the total number of patients studied. Sources: [29, 35–37, 39, 43–45]
Fig. 2 Patients (Very High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, <70 mg/dL (1.81 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, US United States. Notes: Treated and untreated patients. The N represents patients at high risk, a subset of the total number of patients studied. Sources: [29, 35–37, 39, 43–45]CC BY · PubMed Central
Fig. 3 Patients (High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, < 100 mg/dL (2.56 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, US United States. a Primary prevention, 9 months, women. b Primary prevention, 9 months, men. c Based on 2004 guidelines. d Treated and untreated patients. e Treated patients. Sources: [25, 26, 29, 34–36, 39, 43–51]
Fig. 3 Patients (High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, < 100 mg/dL (2.56 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, US United States. a Primary prevention, 9 months, women. b Primary prevention, 9 months, men. c Based on 2004 guidelines. d Treated and untreated patients. e Treated patients. Sources: [25, 26, 29, 34–36, 39, 43–51]CC BY · PubMed Central
Fig. 4 Patients (Moderately High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, < 130 mg/dL (3.0 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, NR not reported, US United States. Note: The N represents patients at high risk, a subset of the total number of patients studied. a Based on data from 2003. b Treated and untreated patients. Sources: [25, 29, 35, 36, 44–53]
Fig. 4 Patients (Moderately High Risk) Not Achieving NCEP-ATP-III Guidelines LDL-C Level Target, < 130 mg/dL (3.0 mmol/L). LDL-C low-density lipoprotein cholesterol, NCEP-ATP-III National Cholesterol Education Program–Adult Treatment Panel III, NR not reported, US United States. Note: The N represents patients at high risk, a subset of the total number of patients studied. a Based on data from 2003. b Treated and untreated patients. Sources: [25, 29, 35, 36, 44–53]CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 3

  1. 5. Cooper A, Nherera L, Calvert N, O'Flynn N, Turnbull N, Robson J, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008. p. 1-236 (revised March 2010).
  2. 15. Austrian Lipid Consensus. Management of dyslipidemia in the prevention of vascular complications. Joint Consensus Statement of Austrian eight professional societies. 2010. http://www.oedg.org/pdf/Lipidkonsensus_2010. pdf (20 May 2014, date last accessed).
  3. 16. Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, et al. Practical implementation of the guidelines for LDL-lowering. J Cardiol. 2011;18(3-4):96-9.

Cited by

See all 40

Metadata

Authors
Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M.
Affiliations
  • RTI Health Solutions (US)
  • Pfizer (United Kingdom) (GB)
  • National University of Singapore (SG)
Corresponding author
Mitchell, S.
Venue
BMC Cardiovascular Disorders
Published
2016-04-26
Volume
16
Issue
1
Pages
74-74
ISSN
1471-2261 (ISSN-L)
OpenAlex
W2342919462
Cited by
40
References
61
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 8 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 8
FWCI
5.91
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Cardiovascular Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Pfizer UK
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
hyperlipidemia, LDL cholesterol targets, cardiovascular risk, high-risk patients, NCEP ATP III guidelines, lipid-lowering therapy, diabetes comorbidity, coronary artery disease, real-world treatment outcomes
MeSH terms
Anticholesteremic Agents, Cardiovascular Diseases, Humans, Hyperlipidemias, Cholesterol, LDL, Risk Factors, Biomarkers, Down-Regulation, Comorbidity, Treatment Outcome, Practice Guidelines as Topic, Risk Assessment, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. https://app.cochat.ai/papers/10.1186/s12872-016-0241-3
The paper
Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M. (2016). Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-016-0241-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.